

# **Long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria in the Phase 3 REMIX-1 and REMIX-2 studies**

*M. Metz, A.M. Giménez-Arnau, M. Hide, V. Jain, A. Khemis, M. Lebwohl, M. Palumbo, S. Saini, E. Şavk, G. Sussman, R. Szalewski, I. Walecka Herniczek, H. Windom, S. Haemmerle, K. Lheritier, Paula G.P. Machado, E-D. Martzloff, N. Seko, P. Wang, A. Zharkov, M. Maurer*

***Please click [HERE](#) to subscribe to news alerts of the Novartis Urticaria Knowledge Center and to receive an email notification once the publication is available***

***Or use this [LINK](#) to access the abstract after 3<sup>rd</sup> June 2024, once it is available at the congress website***